Arca
Skip to content
Tools
Tools

Urinary incontinence

Drug research and approvals for urinary incontinence: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 174 studies of urinary incontinence are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 174
  • Trials authorized in Canada: 7
  • FDA orphan approvals: 0
  • EU medicines: 3

Recruiting now

Newest posted first, of 174 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 11

Phase 3 5

Phase 2 5

Phase 1 or earlier 4

How its trials ended

1,283 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 218 whose ending is known, 47% met their primary endpoint, 5% missed it and 48% stopped early.

  • Completed, result not reported63950%
  • Ongoing23118%
  • Status unknown19515%
  • Met its primary endpoint1038%
  • Stopped: other or unclear655%
  • Stopped: enrollment or feasibility242%
  • Missed its primary endpoint111%
  • Stopped: sponsor or business decision6<1%
  • Stopped: lack of efficacy5<1%
  • Stopped: safety2<1%
  • Stopped: funding2<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Aug 17, 2026A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of berobenatide in adult female participants with stress…Berobenatide (PF-08653944, MET097)PfizerPending
Mar 17, 2026A pilot randomized trial: the effect of local androgenotherapy combined with pelvic floor muscle training on sui in womenPrasteroneCiusss De L'Estrie - Centre Hospitalier Universitaire De SherbrookePending
Sep 12, 2025A master protocol to investigate the efficacy and safety of orforglipron tablet once daily compared with placebo in female participants with stress urinary…Orforglipron (LY3502970)Eli LillyOngoing
Oct 5, 2018A phase 2, multicenter, randomized, double-blind, placebo-controlled, single-treatment, 2-stage, dose-finding study evaluating the efficacy and safety of botox…BotoxAbbVieClosed
Jan 27, 2017A double-blind, randomised, placebo-controlled, parallel-group, phase II, dose-ranging trial to evaluate the efficacy, safety, and tolerability of oral…LitoxetineIxaltisClosed
May 7, 2014Botox in the treatment of urinary incontinence due to overactive bladder in patients 12 to 17 years of ageBotox (onabotulinum)AbbVieOngoing
Dec 16, 2013Botox in the treatment of urinary incontinence due to neurogenic detrusor overactivity in patients 8 to 17 years of ageBotox (onabotulinumtoxina for injection)AbbVieOngoing

Medicines authorised in the EU

Newest first
Oct 22, 2004EmselexDarifenacin hydrobromidepharmaand GmbHEMA ↗
Aug 11, 2004YentreveDuloxetineEli Lilly Nederland B.V.EMA ↗
Jun 15, 2004Kentera (previously Oxybutynin Nicobrand)OxybutyninTeva B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.